According to the company, a booster vaccination with the Corona vaccine from Biontech and Pfizer, which has been adapted to the currently predominant Omicron sublines BA.4/BA.5, is significantly more effective than the original vaccine.
New data from an ongoing clinical trial showed an approximately four-fold increase in neutralizing antibodies against BA.4/BA.5 in the over-55 age group compared to those who received a booster dose of the original vaccine, the company on Friday. Both measurements were reportedly taken one month after the refresher.
Compared to the values before a booster vaccination, a 9.5-fold increase in the so-called antibody titer was found in the group of 18 to 55-year-olds one month after this vaccination. In the over-55s group, there was a 13.2-fold increase. Both vaccines showed comparable safety and tolerability, the companies said.
Blood from dozens of people was tested for the study. The BA.4/BA.5 booster from Biontech/Pfizer has been approved in the EU since mid-September. It contains active ingredients against the original Corona variant and against the omicron sublines BA.4/BA.5.
Message
